Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SP-2577 Seclidemstat · 1 trial · 1 indication
Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0
| Arm | Type | Description |
|---|---|---|
| Sp-2577 | EXPERIMENTAL | Twice-daily administration of oral SP-2577 |
| Name | Type | Description |
|---|---|---|
| SP-2577 Seclidemstat | DRUG | Dose escalation and dose expansion of SP-2577. |
Inclusion Criteria: * Age ≥ 12 years and weight ≥ 40 kg. * Diagnosis of advanced or recurrent, histologically or cytologically confirmed, solid malignancy that is either metastatic or unresectable. At time of enrollment, subjects must have progressed on, be intolerant of, refuse, or ineligible for,...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
SP-2577 Seclidemstat is an investigational small molecule being studied for the treatment of advanced solid tumors. It is being developed by Salarius Pharmaceuticals, Inc. (ticker: DCOY) and is currently in Phase 1 clinical development.
SP-2577 Seclidemstat is an LSD1 inhibitor. It is designed to target the LSD1 enzyme, which plays a role in cancer cell growth. The drug is being evaluated in patients with advanced solid tumors.
SP-2577 Seclidemstat is being developed by Salarius Pharmaceuticals, Inc., a biopharmaceutical company. The company's ticker symbol is DCOY. The drug is currently in Phase 1 clinical development for advanced solid tumors.
SP-2577 Seclidemstat is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 trial has been completed in patients with advanced solid tumors.
SP-2577 Seclidemstat has one completed Phase 1 clinical trial, identified as NCT03895684. The trial was titled 'Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors' and enrolled 23 participants in the United States.